Doxycycline for exacerbations of chronic obstructive pulmonary disease in outpatients: who benefits?
- PMID: 32494571
- PMCID: PMC7248336
- DOI: 10.1183/23120541.00099-2020
Doxycycline for exacerbations of chronic obstructive pulmonary disease in outpatients: who benefits?
Abstract
No clinical characteristics, particularly not sputum characteristics, can guide antibiotic prescription in patients with mild to severe COPD exacerbations https://bit.ly/3e1JV8o.
Copyright ©ERS 2020.
Conflict of interest statement
Conflict of interest: P. van Velzen reports grants from Netherlands Organization for Health Research and Development during the conduct of the study. Conflict of interest: G. ter Riet has nothing to disclose. Conflict of interest: P. Brinkman has nothing to disclose. Conflict of interest: P.J. Sterk reports that he is a scientific advisor to and has a formal, inconsiderable interest in the SME Breathomix BV, outside the submitted work. Conflict of interest: J.M. Prins reports grants from Netherlands Organization for Health Research and Development during the conduct of the study.
Figures
References
-
- Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease https://goldcopd.org/wp-content/uploads/2018/11/GOLD-2019-v1.7-FINAL-14N.... Date last accessed: February 3, 2020.
Grants and funding
LinkOut - more resources
Full Text Sources